How do you taper off Ozempic, Wegovy, or Zepbound without regaining the weight?

Why people taper at all

Evidence tier: 1 — STEP-4 extension RCT (Wilding 2022 + Rubino 2021 JAMA) documenting ~two-thirds weight regain within 12 months of discontinuation.

The default assumption — "you'll be on GLP-1s forever" — isn't accurate for everyone. Some patients reach goal weight and want to stop. Others lose insurance coverage and lose access. Some develop side effects they can't tolerate at maintenance dose. A growing share are deliberately tapering once they hit a target body composition rather than continuing indefinitely.

The honest reality of stopping GLP-1s: most patients regain a meaningful share of lost weight within 12 months of full discontinuation. The STEP-4 extension trial showed roughly two-thirds of weight lost on semaglutide returned within a year of stopping. The mechanism is straightforward — appetite, satiety, and gastric-emptying signals all return to baseline once the drug clears, and the metabolic adaptation that occurred during weight loss often persists.

So the question isn't whether tapering is possible. It's whether you can taper in a way that preserves enough of the gain to matter, and what tools support that process.

The three tapering patterns that actually work

Evidence tier: 5 — Editorial taxonomy synthesizing STEP-4 dose-reduction evidence with clinical practice patterns; not a single RCT-derived protocol.

Pattern 1 — Slow dose reduction over 12-24 weeks. Reduce dose by one increment every 4-6 weeks (e.g., 2.4mg → 1.7mg → 1.0mg → 0.5mg → off for Wegovy). Slower is better; the metabolic re-equilibration time matters. Most patients regain 5-15% of lost weight during this taper, not the 60%+ seen with abrupt discontinuation.

Pattern 2 — Maintenance dose indefinitely. Continue at the lowest dose that maintains weight stability. For many patients this is 0.5-1.0mg/week of semaglutide or 2.5-5mg of tirzepatide. Cost is reduced, side effects are minimal, and weight maintenance is straightforward. This isn't tapering — it's redefining maintenance as a long-term protocol rather than a discontinuation phase.

Pattern 3 — GLP-1 to non-GLP-1 bridge. Taper off GLP-1 while initiating a non-GLP-1 maintenance agent designed to address specific aspects of the post-GLP-1 picture. Most common in 2026: Tesamorelin for visceral adiposity preservation, AOD-9604 (limited evidence) for fat-loss adjunct, structured naltrexone-bupropion (Contrave) for appetite signaling without the GLP-1 mechanism.

The right pattern depends on what's driving the desire to stop. Cost-driven discontinuation usually points to Pattern 2. Side-effect-driven points to Pattern 1 with a longer ramp. Goal-achieved points to either Pattern 2 (if you can afford it) or a hybrid of Pattern 1 + Pattern 3.

What predicts who regains and who doesn't

Evidence tier: 2 — Predictors derived from STEP-1 extension cohort observation and adjacent obesity-medicine literature on lifestyle adherence.

The post-GLP-1 weight regain literature identifies a few consistent predictors of who maintains and who doesn't:

• Behavior change retention — patients who built durable food-environment changes (kitchen contents, restaurant patterns, portion structure) during the GLP-1 phase regain less than those who relied entirely on the drug to suppress appetite.
• Resistance training during weight loss — preserving lean mass during the loss phase substantially reduces post-discontinuation regain.
• Sleep quality — short and disrupted sleep during the maintenance phase strongly predicts regain.
• Continued metabolic monitoring — weekly weights, continuous glucose monitoring data where available, and quarterly bloodwork catch the early signal of regain before it accumulates.

The behavioral predictors are mundane. They are also durable. The medication doesn't replace them; it created a window in which they were easier to install.

The bridge-to-Tesamorelin protocol

Evidence tier: 2 — Tesamorelin VAT reduction (Falutz 2007 NEJM) extrapolated to post-GLP-1 bridge use; combination not RCT-validated.

For patients tapering off GLP-1s with goal-achieved status who want to preserve metabolic gains, the most-discussed 2026 bridge protocol is Tesamorelin maintenance.

Tesamorelin is a 44-amino-acid GHRH analog FDA-approved as Egrifta for HIV-associated visceral adipose tissue reduction. The off-label rationale for the GLP-1 bridge: visceral adiposity is the strongest single predictor of post-GLP-1 cardiometabolic regression, and Tesamorelin specifically reduces VAT by ~15-20% via endogenous GH/IGF-1 elevation.

Standard protocol when used as a GLP-1 bridge: start Tesamorelin at 1mg/day SC during the final 4-week step of the GLP-1 taper, continue 2mg/day for 12-24 weeks post-GLP-1, then re-evaluate based on body composition (DEXA scan, ideally) and metabolic markers (fasting glucose, HbA1c, lipid panel).

This is off-label. It requires a physician familiar with both indications. It's not a substitute for the behavioral foundations above; it's an adjunct that addresses a specific aspect of the post-GLP-1 picture.

Read the full Tesamorelin fact box →

The orforglipron transition path

Evidence tier: 5 — Forward-looking option contingent on pending FDA decision; not yet a clinical-evidence claim.

A meaningfully different 2026 option: rather than fully tapering, transition from injectable GLP-1 to oral orforglipron once it's FDA-approved (PDUFA pending as of writing). Orforglipron's ~14.7% mean weight loss is below tirzepatide and Wegovy's higher numbers, but the convenience profile (oral, no fasting protocol, no injection) shifts the maintenance equation. Many patients who would otherwise discontinue might tolerate oral indefinitely.

This is a wait-and-see option until orforglipron's FDA decision lands. We track the orforglipron deep-dive page for that timing.

Side-effect-driven tapering

Evidence tier: 2 — Adverse event patterns drawn from STEP and SURPASS RCT safety populations and post-marketing surveillance.

Some patients need to discontinue not for goal-achieved reasons but because side effects became intolerable. The common patterns:

• Persistent nausea or GI symptoms at maintenance dose. Try one dose-step reduction first; many patients tolerate 1.7mg semaglutide who couldn't tolerate 2.4mg.
• Gallbladder issues (cholecystitis, cholelithiasis) — a real GLP-1 risk that requires discontinuation or surgical management.
• Severe muscle loss with quality-of-life impact. Stop and pursue resistance training + nutrition support; bridge with Tesamorelin if appropriate.
• Mental health side effects (depression, anxiety, intrusive thoughts) — reported in some patients, controversial in the literature, but if observed clinically should drive discontinuation.

Side-effect tapering uses the same dose-reduction pattern as goal-achieved tapering but with closer monitoring and a faster timeline if symptoms persist.

What 503B compounding cliff means for tapers

Evidence tier: 5 — Regulatory-process section describing how a forced-supply scenario interacts with planned tapering.

The May 4, 2026 FDA proposal excluding semaglutide and tirzepatide from the 503B Outsourcing Facility bulks list creates a forced-tapering scenario for some patients on compounded GLP-1s. If your supply disappears, the four paths in the 503B compounding cliff article apply.

The relevant point for tapering specifically: an unplanned forced discontinuation is meaningfully worse than a planned taper. If you're on compounded GLP-1s and have been considering tapering anyway, doing it now on your terms is much better than having it happen to you.

When to talk to a clinician about tapering

Evidence tier: 5 — Clinical-decision triggers; editorial guidance, not an RCT-derived protocol.

Reasonable triggers for a conversation:

• Reached your weight goal and have maintained it 4+ weeks
• Insurance coverage changing in the next 30-60 days
• Persistent intolerable side effects
• Pregnancy planning (GLP-1s should be discontinued before conception)
• Side effects that emerged after extended use (gallbladder, pancreatitis flags)

Telehealth providers in our clinic directory include several that handle structured taper protocols. The right conversation includes: dose-reduction schedule, monitoring plan (weights, bloodwork, body composition), bridge-agent decision, and behavioral support (registered dietitian referral if you don't already have one).

What we don't recommend

Evidence tier: 5 — Editorial anti-pattern list; reasoning is mechanistic and pragmatic, not from a single trial.

• Cold-turkey discontinuation without a plan
• Switching to research-supplier sources to avoid the regulatory situation
• Self-titrating without monitoring
• Substituting non-FDA peptides (AOD-9604, etc.) without physician supervision
• "I'll just diet harder when I stop" — works in 10-20% of cases, fails in the rest

References

• Wilding JPH, Batterham RL, Calanna S, et al. 2021. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. PMID 33567185
• Rubino D, Abrahamsson N, Davies M, et al. 2021. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults with Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. PMID 33755728
• Wilding JPH, Batterham RL, Davies M, et al. 2022. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. PMID 35441470
• Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. 2023. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. PMID 37952131
• Falutz J, Allas S, Blot K, et al. 2007. Metabolic Effects of a Growth Hormone–Releasing Factor (Tesamorelin) in Patients with HIV. N Engl J Med. PMID 18057338

Limitations

This taper guidance does not apply to patients who are pregnant, planning conception within the next two months, or breastfeeding — GLP-1s should already be discontinued before conception, and tapering should be coordinated with the obstetrician. It also does not apply to patients with active or recent pancreatitis, severe gastroparesis, or medullary thyroid carcinoma history. The Tesamorelin bridge specifically should not be used in patients with active malignancy, diabetic retinopathy, or untreated pituitary disease. Pediatric and adolescent patients are out of scope entirely.

The cited evidence cannot tell us whether structured tapering produces durably better outcomes than maintenance dosing in matched cohorts, what the optimal step size and duration are, whether a Tesamorelin bridge changes the regain trajectory in non-HIV populations, or how oral GLP-1 transition will perform once orforglipron is approved and used at scale.

We would change our framing on three signals: a published taper-vs-maintenance RCT with body-composition endpoints, FDA approval and post-marketing data on orforglipron, or new long-term data from STEP-1 cohorts beyond two years off drug.